Abstract
Myeloablative allogeneic stem cell transplant (MA AlloSCT) for childhood AML may be associated with significant acute toxicity, late effects and/or recurrent disease (Woods et al; Blood, 2001). Reduced intensity (RI) AlloSCT may offer less acute toxicity and/or reduced late effects for children with cancer (Del Toro/Cairo et al; BMT, 2004, Satwani/Cairo, BBMT, 2005). Gemtuzumab ozogamicin (GO) has induced responses in >30% of patients with recurrent CD33+ AML (Sievers et al; J Clin Oncol, 2001).
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
